Rabbit Recombinant Monoclonal HIF-2-alpha antibody. Carrier free. Suitable for IP, WB, ICC/IF and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
IP | WB | ICC/IF | |
---|---|---|---|
Human | Tested | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX1 seems to activate CTAD (By similarity).
BHLHE73, HIF2A, MOP2, PASD2, EPAS1, Endothelial PAS domain-containing protein 1, EPAS-1, Basic-helix-loop-helix-PAS protein MOP2, Class E basic helix-loop-helix protein 73, HIF-1-alpha-like factor, Hypoxia-inducible factor 2-alpha, Member of PAS protein 2, PAS domain-containing protein 2, bHLHe73, HLF, HIF-2-alpha, HIF2-alpha
Rabbit Recombinant Monoclonal HIF-2-alpha antibody. Carrier free. Suitable for IP, WB, ICC/IF and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab222396 is the carrier-free version of Anti-HIF-2-alpha antibody [EPR19656] ab207607.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
HIF-2-alpha also known as hypoxia-inducible factor 2-alpha or EPAS1 plays a significant role in cellular response to oxygen levels. Mechanically HIF-2-alpha functions as a transcription factor that activates certain genes when oxygen is low. The protein typically weighs around 118 kDa. It is expressed in various tissues but particularly in endothelial cells and some neuronal tissues. These sites highlight its importance in organs requiring tight regulation of oxygen.
HIF-2-alpha regulates the expression of genes involved in energy metabolism and angiogenesis. The protein forms a complex by dimerizing with the HIF-1-beta subunit which is necessary for transcriptional activity. Through this complex formation and activity it influences processes such as erythropoiesis and regulates factors like vascular endothelial growth factor (VEGF). Therefore HIF-2-alpha contributes to the adaptation of cells and tissues under hypoxic conditions.
HIF-2-alpha engages in the hypoxia signaling pathway playing an essential part by modulating gene expression in response to low oxygen availability. This role impacts other proteins such as HIF-1-alpha sharing overlapping functions but with distinct target genes. Additionally HIF-2-alpha is involved in the mTOR pathway which influences cell growth and metabolism through its interaction with the nutrient-sensing regulatory pathway.
Researchers have linked HIF-2-alpha with conditions like renal cell carcinoma and pulmonary hypertension. The protein's dysregulation can lead to altered expression of angiogenic factors promoting tumor growth and survival. In particular its connection with VEGF exemplifies its role in these pathologies by facilitating aberrant blood vessel formation. Such interactions further highlight the potential of HIF-2-alpha as a therapeutic target in disease modulation.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
HIF-2-alpha was immunoprecipitated from 0.35 mg HeLa (Human cervix adenocarcinoma epithelial cell) cell treated with 1mM DFO for 24h, cell lysate 10 μg with Anti-HIF-2-alpha antibody [EPR19656] ab207607 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-HIF-2-alpha antibody [EPR19656] ab207607 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: HeLa (Human cervix adenocarcinoma epithelial cell) cell lysate (10 μg) treated with 1mM DFO for 24h
Lane 2: Anti-HIF-2-alpha antibody [EPR19656] ab207607 IP in DFO treated HeLa cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-HIF-2-alpha antibody [EPR19656] ab207607 in HeLa cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 75 seconds
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-HIF-2-alpha antibody [EPR19656] ab207607).
All lanes: Immunoprecipitation - Anti-HIF-2-alpha antibody [EPR19656] (Anti-HIF-2-alpha antibody [EPR19656] ab207607)
Predicted band size: 96 kDa
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (Human epithelial cell line from cervix adenocarcinoma) cells, untreated or treated with deferoxamine mesylate salt (1mM, 24h), labeling HIF-2-alpha with Anti-HIF-2-alpha antibody [EPR19656] ab207607 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) secondary antibody at 1/1000 dilution (green).
Confocal image showing nuclear staining on HeLa cells treated with deferoxamine mesylate salt (1mM, 24h).
The nuclear counterstain is DAPI (blue).
Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889) at 1/200 dilution (red).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) at 1/1000 dilution.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-HIF-2-alpha antibody [EPR19656] ab207607).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com